THC-free RSHO-X™ was at the center of an exciting new study looking at the effects of CBD on children with epilepsy.
The study, performed by renowned physician Dr. Carlos Aguirre-Velazquez, surveyed parents in Mexico and the rest of Latin America who have used CBD as a treatment option for their children’s refractory epilepsy. The results of the study have been recently published in Neurology Research International.
In Dr. Aguirre’s study, structured online surveys were used to record the experiences of parents of children with refractory epilepsy who used medicinal cannabis as a treatment option. In the study, 53 epilepsy cases in children aged between 9 months and 18 years were identified.
The product most commonly used by patients in the survey was HempMeds® Mexico’s flagship product, Real Scientific Hemp Oil-X™ (RSHO-X™). RSHO-X™ was the first cannabis-based product to receive COFEPRIS approval for import into Mexico and is 100% THC-free.
According to the study, several forms of childhood epilepsy were examined. In the 43 cases involving Mexican patients, the diagnoses were as follows: 20 cases (47%) had Lennox-Gastaut syndrome (LGS); 13 cases (30%) had unspecified refractory epilepsy (URE); 8 cases (19%) had West syndrome (WS); 1 case (2%) had Doose syndrome (DS); and 1 case (2%) had Ohtahara syndrome (OS).
The survey, a first-of-its-kind observational study in Mexico exploring the use of medicinal cannabis in the form of CBD in the treatment of refractory epilepsy in children, reported that out of the 43 cases in Mexico, 51% of patients showed a significant (greater than 75%) decrease in convulsions, while 16% reported being completely seizure free.
“These new survey findings where the improvements reported by the parents were related not only to the frequency of the seizures, but also their duration and intensity, come on the heels of another critical study recently performed in Mexico with our Company’s RSHO-X™ product, which also showcased the therapeutic benefits of hemp-based botanical CBD,” said Raul Elizalde of HempMeds® Mexico. “We are excited that new evidence on how CBD oil is providing epileptic children with relief continues to emerge in Mexico and we expect this news to spread and help patients all across the world.”
In total, 47% of the cases in the study had previously been treated with 9 or more anticonvulsant therapies. When cannabidiol was used, the parents reported a decrease in convulsions in over 81% of the cases. A moderate to significant decrease in seizures occurred in 51% of cases. Finally, in 16% of the cases, patients using CBD were reported as going seizure free.
The study also revealed that the use of CBD led to a decrease in the use of other seizure medications. The number of antiepileptic drugs being used by patients in the study was reduced in 9 out of 43 (20.9%) cases.
No serious adverse effects were reported by participants, with only some mild side effects, such as increased appetite or changes in sleep patterns, reported in 42% of cases. The survey reported an overall increased quality of life of the patients – with 88% showing improved cognition, 86% showing improved emotions or mood, 77% showing an improvement in sleep, and 67% showing a better appetite.
Reliable treatment options for epilepsy patients is a critical health care need in Mexico and abroad. According to information included in a press release announcing the study, epilepsy is a common and chronic neurological disorder that affects over 50 million people worldwide. Nearly 2.4 million new cases of epilepsy are diagnosed every year, according to the World Health Organization. In Mexico alone, 1.5 million patients have epilepsy, with 80% of patients receiving inadequate treatment, while 30% of patients have refractory epilepsy, an epilepsy defined as a failure to respond to anti-epileptic drugs.
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.